Monopar Therapeutics Inc. (MNPR)

Monopar Therapeutics

Monopar Therapeutics is a clinical-stage biotechnology company developing novel radiopharmaceuticals for oncology and a new treatment for Wilson Disease, a rare genetic disorder. Its pipeline includes radiopharmaceuticals targeting advanced solid tumors and late-stage ALXN1840, a treatment for Wilson Disease. The radiopharma programs targeting advanced cancers include clinical-stage MNPR-101-Zr for imaging, and for therapy, clinical-stage MNPR-101-Lu and late-preclinical stage MNPR-101-Ac. Monopar builds its drug development pipeline through in-house efforts and licensing of late preclinical and clinical-stage therapeutics, leveraging its scientific and clinical expertise to reduce risk and accelerate development.

Monopar's team is located in Chicago, IL.

Why Oncology?

Monopar is developing personalized and precise radiopharmaceuticals to diagnose and treat aggressive cancers.

Approximately one in every two individuals will develop cancer during their lifetime.
Cancer is one of the leading causes of death worldwide and the second leading cause of death in the United States and Europe, accounting for nearly 1 in 4 deaths in the US.
Just as no two people are the same, no two cancers are the same. We believe the future of cancer treatment will be personalized and precise.
We see the emerging field of radiopharmaceuticals as transforming cancer care through its personalized and precise approach to treatment.

MNPR-101-Zr, MNPR-101-Lu, & MNPR-101-Ac

Why Rare Disease?

Monopar recently in-licensed bis-choline tetrathiomolybdate (ALXN1840), a late-stage investigational drug to treat Wilson Disease.

Our team consists of individuals with deep experience in rare diseases, including co-founding the successful orphan drug development companies BioMarin, Raptor Pharma, and Wilson Therapeutics.
Our CEO has a long history with Wilson Disease, including a publication in Science on tetrathiomolybdate and helping launch a Wilson Disease focused company around what became known as ALXN1840.
We share a passion for helping bring treatments to patients who often have limited options.

ALXN1840

Corporate Overview

Our management team has extensive experience in building companies and developing therapeutics through regulatory approval and commercialization.

Discover

Our Research Pipeline

Monopar's pipeline includes radiopharmaceuticals targeting advanced solid tumors and late-stage ALXN1840, a treatment for Wilson Disease. The radiopharma programs targeting advanced cancers include clinical-stage MNPR-101-Zr for imaging, and for therapy, clinical-stage MNPR-101-Lu and late-preclinical stage MNPR-101-Ac.

Product	Indications	Discovery	Preclinical	Phase 1	Phase 2	Phase 3	Status
ALXN1840 (Rare Disease)	Wilson Disease	Discovery complete	Preclinical complete	Phase 1 complete	Phase 2 complete	Phase 3 in progress	Phase 3 Complete
MNPR‑101‑Zr (Oncology)	Advanced Solid Cancers (Imaging)	Discovery complete	Preclinical in progress	Phase 1 not started	Phase 2 not started	Phase 3 not started	Phase 1 Clinical Trial Active and Recruiting
MNPR-101-Lu (Oncology)	Advanced Solid Cancers	Discovery complete	Preclinical in progress	Phase 1 not started	Phase 2 not started	Phase 3 not started	Phase 1a Clinical Trial Active and Recruiting
MNPR-101-Ac (Oncology)	Advanced Solid Cancers	Discovery complete	Preclinical in progress	Phase 1 not started	Phase 2 not started	Phase 3 not started	Late Preclinical
Early Pipeline (Oncology)	Solid cancers	Discovery complete	Preclinical in progress	Phase 1 not started	Phase 2 not started	Phase 3 not started	Early Preclinical
Early Pipeline (Oncology)	Solid cancers	Discovery in progress	Preclinical not started	Phase 1 not started	Phase 2 not started	Phase 3 not started	Discovery

Email Alerts

Stay informed and receive company updates straight to your inbox

Personalized & Precise

ALXN1840 (Rare Disease)

MNPR‑101‑Zr (Oncology)

MNPR-101-Lu (Oncology)

MNPR-101-Ac (Oncology)

Early Pipeline (Oncology)

Early Pipeline (Oncology)